Literature DB >> 8794504

Cortical gray matter volume deficits in schizophrenia: a replication.

K O Lim1, E V Sullivan, R B Zipursky, A Pfefferbaum.   

Abstract

We sought to replicate an earlier finding of widespread deficit in cortical gray matter in schizophrenia by testing new samples of 22 schizophrenic patients and 27 controls between the ages of 21-46 years. Brain values for both patients and controls were standardized against age and head size norms derived from a larger control group (n = 73) spanning a wider age range (21-70). Compared to the new age-matched controls, the new schizophrenic sample showed a deficit in gray matter volume affecting the cortex as a whole and enlargement of the lateral and third ventricles. Thus, widespread cortical gray matter deficit is a replicable feature of the brain dysmorphology of schizophrenia in young to middle-aged men.

Entities:  

Mesh:

Year:  1996        PMID: 8794504     DOI: 10.1016/0920-9964(95)00081-x

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  9 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 2.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

3.  The contributions of disease and genetic factors towards regional cortical thinning in schizophrenia: the UCLA family study.

Authors:  Yaling Yang; Keith H Nuechterlein; Owen Phillips; Liberty S Hamilton; Kenneth L Subotnik; Robert F Asarnow; Arthur W Toga; Katherine L Narr
Journal:  Schizophr Res       Date:  2010-11       Impact factor: 4.939

4.  Cerebral atrophy and white matter disruption in chronic schizophrenia.

Authors:  Nicola Andreone; Michele Tansella; Roberto Cerini; Gianluca Rambaldelli; Amelia Versace; Giovanna Marrella; Cinzia Perlini; Nicola Dusi; Luisa Pelizza; Matteo Balestrieri; Corrado Barbui; Michela Nosè; Anna Gasparini; Paolo Brambilla
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-02       Impact factor: 5.270

5.  Structural brain abnormalities in patients with schizophrenia and 22q11 deletion syndrome.

Authors:  Eva W C Chow; Robert B Zipursky; David J Mikulis; Anne S Bassett
Journal:  Biol Psychiatry       Date:  2002-02-01       Impact factor: 13.382

Review 6.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia.

Authors:  Serge A Mitelman; Adam M Brickman; Lina Shihabuddin; Randall E Newmark; Erin A Hazlett; M Mehmet Haznedar; Monte S Buchsbaum
Journal:  Neuroimage       Date:  2007-05-24       Impact factor: 6.556

8.  Reduced gray matter volume in psychotic disorder patients with a history of childhood sexual abuse.

Authors:  Julia M Sheffield; Lisa E Williams; Neil D Woodward; Stephan Heckers
Journal:  Schizophr Res       Date:  2012-11-22       Impact factor: 4.939

9.  In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging.

Authors:  J Foong; M Maier; G J Barker; S Brocklehurst; D H Miller; M A Ron
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-01       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.